Option Chain

Abivax ADR

ABVXNASDAQ · USD

87.58USD0.00 (-2.91%)

225

Abivax ADR (ABVX) Option Chain

Abivax ADR trades at $87.58, down 2.91%, with an IV Rank of 5.16%. This is low versus the past year, and the company carries a market cap of $7,668M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $88.00 strike shows calls at $1.75 / $3.60 and puts at $1.45 / $4.90, both carrying about $2.71 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $100.00 calls, at 545 contracts, and the $75.00 puts, at 94, as of Nov 13, 2026.

Tracking the ABVX option chain helps you see every strike and expiry on Abivax ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ABVX options activity at a glance. Use our scanner to monitor the ABVX option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ABVX stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ABVX options are being actively traded, and where they are not.

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
42.78	7	0	2.52	1.58	2.80	5.40	86.00	-1.80	1.85	3.60	0.00	2.73	1	6	57.22
48.20	41	11	2.87	0.58	3.00	3.90	87.00	-0.66	1.05	4.40	0.00	2.73	24	14	51.80
53.58	8	128	2.68	0.00	1.75	3.60	88.00	+0.48	1.45	4.90	0.42	2.75	24	137	46.42
56.23	11	0	2.93	0.00	1.65	4.20	88.50	+1.05	1.75	4.90	0.92	2.40	0	3	43.77
58.84	505	0	2.35	0.00	1.30	3.40	89.00	+1.62	2.05	4.80	1.42	2.00	0	2	41.16

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank5.16% Low
Market cap (M$)7,668
52 weeks high-41.15%
52 weeks low25.45%
Analyst recommendationStrong Buy
1.28
Target price$157.26
79.56% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-12-21
P/E—
Future P/E—
EPS (ttm)-6.10
EPS growth next 5 years34.25%

As of Nov 13, 2026

Browse all Option Chain tickers